Clinical Bioanalysis

NoobTron Healthcare provides end-to-end large-molecule bioanalytical services for early to late-phase clinical trials, integrating advanced analytical technologies with established quality systems. Laboratories operate under strict GCP and GLP standards and utilize high-sensitivity platforms for precise pharmacokinetic, immunogenicity, and biomarker analyses. Extensive experience in biotherapeutics enables accurate, reproducible, and audit-ready data generation that supports regulatory submissions, strengthens decision-making, and advances clinical development programs with confidence.

Speak to Our Scientist

PK/PD and Immunogenicity Testing with Cutting-Edge Bioanalytical Platforms

NoobTron provides comprehensive clinical bioanalysis services, offering method development, validation, and sample analysis using advanced LC-MS/MS and Ligand Binding Assay (LBA) platforms, including ELISA and ECL. Our bioanalytical capabilities are designed to support drug development and regulatory submissions, delivering sensitive, specific, and reproducible results tailored to biotherapeutics.

Quantification of Free/Bound/Total Drug Concentrations in Biological Matrices, ensuring accurate Pharmacokinetic (PK) and Pharmacodynamic (PD) analysis.

Anti-Drug Antibody(ADA) Testing
Utilizing a tiered approach for :

  • Screening
  • Confirmatory
  • Titer

Neutralizing Antibody (NAb) Detection: Conducted through Cell-Based or Competitive Ligand Binding (CLB) Assays for precise immunogenicity assessment.

Biomarker Estimations: Leveraging innovative technologies for accurate biomarker analysis, supporting in-depth clinical evaluations.

Our Expertise in Large-Molecule Therapeutics

NoobTron Healthcare supports bioanalytical assays for a broad spectrum of large‑molecule therapeutics, backed by experience that spans discovery through late‑stage development. The scientific team has contributed to development and testing of multiple approved biologics, demonstrating strong modality‑specific know‑how and familiarity with current regulatory expectations.

Enhancing Assay Precision with Advanced Critical Reagent Development:

NoobTron provides specialized critical reagent development services to ensure the highest levels of accuracy and consistency in your Ligand Binding Assays. Using cutting-edge characterization techniques, we optimize critical reagents for superior specificity, affinity, stability, and purity. This enables precise, reproducible measurement of target analytes in biological matrices, essential for reliable assay performance.

Key Strengths Include:

  • Biosimilars and monoclonal antibodies
  • Antibody–Drug Conjugates (ADCs)
  • Bi‑specific and Tri‑specific proteins
  • Enzyme replacement therapies
  • Recombinant proteins

Bioanalytical Services Across Drug Development

NoobTron Healthcare provides regulatory-compliant bioanalytical support across all stages of drug development, including GLP, GCLP, and GMP studies. With standardized SOPs across multiple global sites, we deliver consistent, reliable results that meet regulatory expectations worldwide. Our flexible processes enable close collaboration with clients throughout the full lifecycle of their therapeutic programs, offering a complete suite of bioanalytical services tailored to every development and regulatory stage.

Pharmacokinetics (PK)

NoobTron Healthcare delivers pharmacokinetic evaluations essential for understanding the absorption, distribution, metabolism, and elimination of therapeutics. PK studies provide insights to guide dosage, administration routes, and treatment schedules, supporting safe and effective therapeutic development from preclinical through clinical stages. Regulatory-compliant practices ensure accurate, reproducible data that informs critical development decisions.

Immunoassay/Ligand-Binding Assays

NoobTron Healthcare develops and validates quantitative immunoassay and ligand‑binding methods for therapeutic proteins, soluble and cell‑associated biomarkers, and anti‑drug antibodies. Assay formats are configured for defined dynamic range, sensitivity, drug/target tolerance, and matrix effect control, enabling reliable PK, PD, and immunogenicity readouts across study phases.

NoobTron Healthcare performs LC/MS bioanalysis using high‑performance chromatographic separation coupled to triple‑quadrupole and high‑resolution mass spectrometry. Methods are developed and validated under GxP guidelines with electronic records meeting 21 CFR Part 11 handling, supporting precise quantification of small molecules, peptides, metabolites, and complex formulations, including stability‑indicating and metabolite‑profiling workflows.

NoobTron Healthcare conducts molecular assays on qPCR and ddPCR platforms for quantitative detection of DNA and RNA targets, copy‑number determination, and vector genome titration. These assays support nucleic acid therapeutics, viral vectors, and genetic biomarkers, with designs optimized for specificity, limit of detection, and sample‑matrix compatibility in discovery, preclinical, and clinical studies.

NoobTron Healthcare runs multi‑colour, high‑parameter flow cytometry for immunophenotyping, receptor occupancy, and functional biomarker analysis. Panel design, instrument setup, and data analysis pipelines are standardized to ensure reproducible identification of cell subsets and activation states in complex matrices such as whole blood, PBMCs, and tissue‑derived suspensions.

Pharmacodynamics (PD)

PD assessments in early drug development studies can provide vital information on biological effects to help the design of later clinical studies to improve treatment. PD biomarkers are used in preclinical and clinical studies for establishing dosing regimens and therapeutic efficacy.

Immunogenicity

Immunogenicity risk assessment is critical to the development of most therapeutic modalities. It can affect both safety and efficacy, ranging from no evidence of clinical effect to severe, life-threatening responses. Assessment of undesirable immunogenicity of therapeutics is a key element in drug development.

Immunogenicity Evaluation Framework

Assessment includes ADA and NAb detection, cellular immunogenicity profiling (ELISpot, flow cytometry), cytokine quantification, reagent characterization, surrogate control generation, and statistical modeling for cut-point establishment using platforms such as ELISA, MSD, Gyrolab, Biacore, ImmunoCAP, Luminex, and flow cytometry.

Advanced analytical systems are applied to determine immune activation, characterize antibody responses, define incidence and kinetics of ADA formation, and assess neutralizing capacity, cross-reactivity, and potential clinical impact for large molecules and ATMPs.

Immunogenicity data support prediction of immune-mediated adverse effects by mapping adaptive and innate immune responses, enabling accurate interpretation of safety signals and therapeutic performance across complex biologic modalities.

Biomarkers

Biomarker analysis enables you to assess a therapeutic’s efficacy, safety, and mechanism of action to make go/no go decisions during the drug development process. Biomarker assays can also validate targets and identify potential toxicity.

Optimal Platforms for Biomarker Studies

Biomarker analysis enables you to assess a therapeutic’s efficacy, safety, and mechanism of action to make go/no go decisions during the drug development process. Biomarker assays can also validate targets and identify potential toxicity.

Immunoassay Systems: ELISA, MSD-ECL, Gyrolab, Luminex, ProteinSimple Ella, LI-COR Odyssey

Biomarker-Specific Tools: ST2 biomarker assays

Molecular and Analytical Platforms: qPCR, ddPCR, LC-HRMS, HPLC, Quanterix

CMC Bioanalytical

CMC bioanalytical testing is required for all drug development programs. These assays are used to monitor the drug manufacturing processes and ensure the safety, efficacy, and quality of pharmaceutical products. CMC bioanalytical strategies are inherently complex and must be individualized for each therapeutic program.

Cell Line / Clone Selection
  • Protein sequence verification & GOI
  • Sequence variants characterization
  • Post-translational modification(PTM) analysis
  • Glycosylation analysis
  • De novo sequencing
  • Biomarkers / cellular indicators
  • Activated / deactivated target genes
  • Genome titer / viral titer
  • Infection / transfection / transduction efficiency
  • Capsid / viral particle number
  • Trace impurities
  • Host cell proteins
  • Residual host DNA
  • Residual insulin / antibiotics / process residuals
  • Residual plasmid
  • Cell‑based platforms: Functional potency assays, proliferation assays, ADCC/CDC, neutralization assays
  • Immunoassays: Ligand‑binding assays, biomarker quantification, residual impurity detection
  • Molecular assays: qPCR/ddPCR, vector copy‑number analysis, gene‑expression profiling
  • Image‑based analytics: High‑content imaging readouts, infection/transfection assessment
  • Enzymatic and MS‑based methods: Enzyme activity assays, structural characterization, and trace analysis by mass spectrometry
  • Integrated feasibility, optimization, and MoA-aligned method development
  • Phase-appropriate qualification and full ICH-compliant validation (Q2(R2), Q14)
  • Seamless tech transfer, comparability, and bridging studies
  • Visual appearance & clarity checks
  • Container closure integrity
  • Sub-visible particle and particulate matter analysis
  • Compendial parameters: pH, osmolality, conductivity, basic wet chemistry

Applications across modalities and regulatory stages

NoobTron Healthcare supports biologics and advanced therapeutic platforms across IND to BLA stages and beyond, including monoclonal antibodies, bi-/tri-specific antibodies, antibody–drug conjugates, proteins, peptides, fusion proteins, vaccines, gene therapies, and cell-based therapies.

“With an integrated network of specialized laboratories and a senior CMC and bioanalytics team, NoobTron Healthcare enables sponsors to anticipate and resolve critical CMC challenges, keeping development programs on specification, on time, and in regulatory alignment.”